Biotechnology

The research giant took a massive Q4 loss from asset impairments but points to improving client demand and a strategic overhaul as signs of a turnaround.

A new biotech emerges with massive funding and a next-gen 'shuttle' to deliver safer, more effective Alzheimer's therapies directly to the brain.

Positive early trial data for ZP9830 shows promise for a new class of targeted autoimmune therapies, marking a strategic pivot for Zealand Pharma.

A new hair-root innovation from Thai universities uses Riceberry rice to fight hair loss at the cellular level, boosting local farmers and global markets.

As Jazz Pharmaceuticals preps for key investor talks, all eyes are on its blockbuster pipeline, revenue growth, and strategy to fend off competition.

With a $50.1M financing led by top investors, Coherus solidifies its strategic pivot from biosimilars to a pure-play oncology powerhouse.

Genmab posts record 2025 revenue, driven by cancer drug sales and a major acquisition, setting an ambitious, investment-heavy course for 2026.

Primex Inc. hires a life sciences expert to drive its OneVue Sense solution deeper into the critical and highly regulated healthcare and biopharma markets.

As Adagene presents at key conferences, its SAFEbody tech and lead drug muzastotug draw focus amid a strategic push for funding and partnerships.

The largest study of its kind reveals metabolic signatures that predict severe neurotoxicity in CAR T-cell patients, paving the way for safer treatments.

The American Diabetes Association is funding seven visionary scientists using AI, CRISPR, and stem cells to forge the next frontier in diabetes treatment.

Sanofi promotes Dupixent growth driver Manuela Buxo to lead its crucial Specialty Care unit, ensuring continuity as competition and a new AI focus intensify.

A major patent deal shields Esperion's flagship drugs from generics, securing future revenue but delaying cheaper options for millions of patients.

A partnership between NSA Labs and Proscia is slashing study times for brain research, showing how digital platforms are key to finding new therapies faster.

A new oral drug from Nimbus Therapeutics uses AI-driven precision to fight inflammation and repair tissue, offering new hope for millions with IBD.

With demand for freeze-drying surging, OFD adds project management veteran Danielle Grosso to its expanding leadership team to scale operations.

As Revvity execs prepare for key conferences, investors will watch for clues on AI strategy, growth guidance, and margin recovery after a mixed 2025.

An independent board again backs the safety of BriaCell's metastatic breast cancer therapy in a pivotal Phase 3 trial, boosting hope for a new treatment.

With a bolstered balance sheet and a sharpened focus, Palatin Technologies is advancing two novel obesity drugs into clinical trials for rare genetic disorders.

Landmark study in JAMA Neurology shows BRIUMVI offers near-zero relapse rates and stable disability, reshaping long-term multiple sclerosis treatment.